Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Health Care Fund”. The ...

Merck & Co. has significantly outperformed the broader market, while higher earnings guidance and bullish analyst sentiment ...

Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...

The placebo-controlled, randomised, double-blind study plans to enrol around 2,136 patients across 28 countries.

Merck & Co. has called time on a Sutro Biopharma-partnered IL-2 agonist that was being tested for solid tumors, Fierce has ...

Merck & Co., Inc. announced its third-quarter 2026 financial results, reporting total worldwide sales of $18.1 Billion, which ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong ...

Merck & Co. (NYSE:MRK) extended its bullish run into a seventh straight session, with shares trading 1.56% higher at $121.62 on Friday afternoon. Over the preceding six sessions, the company’s shares ...

'Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product ...